- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
Patent holdings for IPC class A61P 13/12
Total number of patents in this class: 6078
10-year publication summary
|
136
|
259
|
328
|
348
|
464
|
438
|
460
|
500
|
470
|
71
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Daiichi Sankyo Company, Limited | 1875 |
97 |
| Amicus Therapeutics, Inc. | 353 |
58 |
| Boehringer Ingelheim International GmbH | 4580 |
45 |
| Osaka University | 3348 |
41 |
| Novartis AG | 10462 |
38 |
| Takeda Pharmaceutical Company Limited | 2715 |
37 |
| Mitsubishi Tanabe Pharma Corporation | 540 |
36 |
| F. Hoffmann-La Roche AG | 7879 |
33 |
| Eli Lilly and Company | 3975 |
33 |
| Chugai Seiyaku Kabushiki Kaisha | 1387 |
32 |
| Nippon Shinyaku Co., Ltd. | 323 |
31 |
| Bayer Pharma AG | 1035 |
30 |
| Vertex Pharmaceuticals Incorporated | 1611 |
30 |
| Mayo Foundation for Medical Education and Research | 3340 |
30 |
| Sunshine Lake Pharma Co., Ltd. | 613 |
30 |
| The Regents of the University of California | 20427 |
29 |
| AstraZeneca AB | 2829 |
29 |
| Tohoku University | 2885 |
28 |
| Bristol-myers Squibb Company | 4792 |
25 |
| Hoffmann-La Roche Inc. | 3628 |
25 |
| Other owners | 5341 |